Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Pfizer (PFE) is back in focus after reporting first quarter 2026 results that topped analyst expectations, reaffirmed its ...
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...
Hosted on MSN
Pfizer tops Q1 forecasts but guidance underwhelms
Pfizer reported first-quarter 2026 revenue of $14.45 billion, up 5.4% year over year and above Wall Street estimates, with adjusted EPS of $0.75 also topping forecasts. Despite the beat, the company ...
LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the ...
Pfizer’s GLP-1 weight management treatment Xianweiying, is reportedly available for pre-order in China in the wake of intensifying competition with rivals in a market analysis expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results